Search

Your search keyword '"Cabezudo, Elena"' showing total 31 results
Start Over Author "Cabezudo, Elena"
31 results on '"Cabezudo, Elena"'

1. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Author

Rosiñol, Laura, Oriol, Albert, Ríos, Rafael, Blanchard, María Jesús, Jarque, Isidro, Bargay, Joan, Hernández, Miguel Teodoro, Cabañas, Valentín, Carrillo-Cruz, Estrella, Sureda, Anna, Martínez-López, Joaquín, Krsnik, Isabel, González, Maria Esther, Casado, Luis Felipe, Martí, Josep María, Encinas, Cristina, de Arriba, Felipe, Palomera, Luis, Sampol, Antonia, González-Montes, Yolanda, Cabezudo, Elena, Paiva, Bruno, Puig, Noemí, Cedena, María Teresa, de la Cruz, Javier, Mateos, María-Victoria, San Miguel, Jesús, Lahuerta, Juan José, and Bladé, Joan

Published
2023
Full Text
View/download PDF

4. What matters most to patients with multiple myeloma? A Pan-European patient preference study

Author

Janssens, Rosanne, primary, Lang, Tamika, additional, Vallejo, Ana, additional, Galinsky, Jayne, additional, Morgan, Kate, additional, Plate, Ananda, additional, De Ronne, Chris, additional, Verschueren, Margaux, additional, Schoefs, Elise, additional, Vanhellemont, Anneleen, additional, Delforge, Michel, additional, Schjesvold, Fredrik, additional, Cabezudo, Elena, additional, Vandebroek, Martina, additional, Stevens, Hilde, additional, Simoens, Steven, additional, and Huys, Isabelle, additional

Published
2022
Full Text
View/download PDF

5. P-203: Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)

Author

Oriol, Albert, primary, Canelo-Vilaseca, Marta, additional, Sanchez, Carla, additional, Abril, Laura, additional, Escoda, Lourdes, additional, Ibarra, Gladys, additional, Abella, Eugenia, additional, Motllo, Cristina, additional, Gonzalez-Montes, Yolanda, additional, Granada, Isabel, additional, Cabezudo, Elena, additional, Senin, Alicia, additional, Ben, Randa, additional, Jurado, Rebeca, additional, de Jaureguizar, Alejandro, additional, Ribera, Josep-Maria, additional, Sarra, Josep, additional, Sancho, Juan-Manuel, additional, and Sureda, Anna, additional

Published
2022
Full Text
View/download PDF

6. What matters most to patients with multiple myeloma? A Pan-European patient preference study

Author

Janssens, Rosanne, Lang, Tamika, Vallejo, Ana, Galinsky, Jayne, Morgan, Kate, Plate, Ananda, De Ronne, Chris, Verschueren, Margaux, Schoefs, Elise, Vanhellemont, Anneleen, Delforge, Michel, Schjesvold, Fredrik, Cabezudo, Elena, Vandebroek, Martina, Stevens, Hilde, Simoens, Steven, Huys, Isabelle, Janssens, Rosanne, Lang, Tamika, Vallejo, Ana, Galinsky, Jayne, Morgan, Kate, Plate, Ananda, De Ronne, Chris, Verschueren, Margaux, Schoefs, Elise, Vanhellemont, Anneleen, Delforge, Michel, Schjesvold, Fredrik, Cabezudo, Elena, Vandebroek, Martina, Stevens, Hilde, Simoens, Steven, and Huys, Isabelle

Abstract

Introduction: Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods for quantifying patients’ preferences. Methods: A survey incorporating DCE and SW was disseminated among European MM patients. The survey included attributes and levels informed by a previous qualitative study with 24 MM patients. Latent class and mixed logit models were used to estimate the DCE attribute weights and descriptive analyses were performed to derive SW weights. MM patients and patient organisations provided extensive feedback during survey development. Results: 393 MM patients across 21 countries completed the survey (Myears since diagnosis=6; Mprevious therapies=3). Significant differences (p<.01) between participants’ attribute weights were revealed depending on participants’ prior therapy experience, and their experience with side-effects and symptoms. Multivariate analyses showed that participants across the three MM patient classes identified via the latent class model differed regarding their past number of therapies (F=4.772, p=.009). Patients with the most treatments (class 1) and those with the least treatments (class 3) attached more value to life expectancy versus quality of life-related attributes such as pain, mobility and thinking problems. Conversely, patients with intermediary treatment experience (class 2) attached more value to quality of life-related attributes versus life expectancy. Participants highlighted the difficulty of trading-off between life expectancy and quality of life and between physical and mental health. Participants expressed a need for greater psychological support to cope with their symptoms, treatment side-effects, and uncertainties. With respect to patients’ preferences for the DCE or SW questions, 42% had no prefe, IMI-PREFER

Published
2022
Full Text
View/download PDF

7. Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Author

Rosinol, Laura, primary, Oriol, Albert, additional, Ríos Tamayo, Rafael, additional, Blanchard, María Jesús, additional, Jarque, Isidro, additional, Bargay, Joan, additional, Hernández, Miguel-Teodoro, additional, Moraleda, Jose Maria, additional, Carrillo-Cruz, Estrella, additional, Sureda, Anna, additional, Martínez-López, Joaquín, additional, Krsnik, Isabel, additional, Garcia, Esther González, additional, Casado, Felipe, additional, Marti, Josep M, additional, Encinas, Cristina, additional, De Arriba, Felipe, additional, Palomera, Luis, additional, Sampol, Antonia, additional, Gonzalez-Montes, Yolanda, additional, Cabezudo, Elena, additional, Mateos, Maria-Victoria, additional, San-Miguel, Jesus, additional, Lahuerta, Juan Jose, additional, and Bladé Creixenti, Joan, additional

Published
2021
Full Text
View/download PDF

8. P-115: Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)

Author

Garcia-Guiñón, Antonio, primary, Morales, Enrique, additional, Sureda, A, additional, González-García, Esther, additional, Durán, María Soledad, additional, Escalante, Fernando, additional, Gironella, M, additional, González-López, Tomás José, additional, Duro, Rafael, additional, Encinas, Manuel Pérez, additional, Ribas, Paz, additional, Cabezudo, Elena, additional, García, Rafael Lluch, additional, Español, Ignacio, additional, Cabanas, Valentín, additional, García-Muñoz, Ricardo, additional, Márquez, José Antonio, additional, Navarro, Mireya, additional, and de la Rubia, Javier, additional

Published
2021
Full Text
View/download PDF

9. Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study

Author

Janssens, Rosanne, primary, Lang, Tamika, additional, Vallejo, Ana, additional, Galinsky, Jayne, additional, Plate, Ananda, additional, Morgan, Kate, additional, Cabezudo, Elena, additional, Silvennoinen, Raija, additional, Coriu, Daniel, additional, Badelita, Sorina, additional, Irimia, Ruxandra, additional, Anttonen, Minna, additional, Manninen, Riikka-Leena, additional, Schoefs, Elise, additional, Vandebroek, Martina, additional, Vanhellemont, Anneleen, additional, Delforge, Michel, additional, Stevens, Hilde, additional, Simoens, Steven, additional, and Huys, Isabelle, additional

Published
2021
Full Text
View/download PDF

10. Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study

Author

Janssens, Rosanne, Lang, Tamika, Vallejo, Ana, Galinsky, Jayne, Plate, Ananda, Morgan, Kate, Cabezudo, Elena, Silvennoinen, Raija, Coriu, Daniel, Badelita, Sorina, Irimia, Ruxandra Maria, Antonnen, Minna, Manninen, Riikka-Leena, Schoefs, Elise, Vandebroek, Martina, Vanhellemont, Anneleen, Delforge, Michel, Stevens, Hilde, Simoens, Steven, Huys, Isabelle, Janssens, Rosanne, Lang, Tamika, Vallejo, Ana, Galinsky, Jayne, Plate, Ananda, Morgan, Kate, Cabezudo, Elena, Silvennoinen, Raija, Coriu, Daniel, Badelita, Sorina, Irimia, Ruxandra Maria, Antonnen, Minna, Manninen, Riikka-Leena, Schoefs, Elise, Vandebroek, Martina, Vanhellemont, Anneleen, Delforge, Michel, Stevens, Hilde, Simoens, Steven, and Huys, Isabelle

Abstract

info:eu-repo/semantics/inPress

Published
2021

11. Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study

Author

Cejalvo, María J., Legarda, Mario, Abella, Eugènia, Cabezudo, Elena, Encinas, Cristina, García-Feria, Ana, Gironella, Mercedes, Íñigo, Belén, Martín, Jesús, Ribas, Paz, Ruiz, M. Ángeles, González, Yolanda, Vicuña, Isabel, Ramírez, Ángel, Fernández, Pascual, Rubia, Javier de la, Cejalvo, María J., Legarda, Mario, Abella, Eugènia, Cabezudo, Elena, Encinas, Cristina, García-Feria, Ana, Gironella, Mercedes, Íñigo, Belén, Martín, Jesús, Ribas, Paz, Ruiz, M. Ángeles, González, Yolanda, Vicuña, Isabel, Ramírez, Ángel, Fernández, Pascual, and Rubia, Javier de la

Published
2020

12. Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma

Author

Oriol, Albert, primary, Ibarra, Gladys, additional, Abella, Eugènia, additional, Motlló, Cristina, additional, Cibeira, Maria-Teresa, additional, Garcia, Antoni, additional, Escoda, Lourdes, additional, Granell, Miquel, additional, Ben-Azaiz, Randa, additional, Cervera, Marta, additional, Cabezudo, Elena, additional, Fernandez, Carlos, additional, and Rosiñol, Laura, additional

Published
2020
Full Text
View/download PDF

13. Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study

Author

Cejalvo, María J., primary, Legarda, Mario, additional, Abella, Eugenia, additional, Cabezudo, Elena, additional, Encinas, Cristina, additional, García‐Feria, Ana, additional, Gironella, Mercedes, additional, Iñigo, Belén, additional, Martín, Jesús, additional, Ribas, Paz, additional, Ruíz, Mª Ángeles, additional, González, Yolanda, additional, Vicuña, Isabel, additional, Ramírez, Ángel, additional, Fernández, Pascual, additional, and Rubia, Javier, additional

Published
2019
Full Text
View/download PDF

14. Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Author

González-Barca, Eva, primary, Martín, Alejandro, additional, Bello, Jose Luis, additional, Bergua Burgues, Juan Miguel Miguel, additional, Panizo, Carlos, additional, Encuentra, Maite, additional, Monter Rovira, Ana, additional, Cordoba, Raul, additional, Bastos, Mariana, additional, Sanchez Blanco, Jose Javier, additional, Gomez, Pilar, additional, Marin Niebla, Ana, additional, González de Villambrosia, Sonia, additional, Sayas, Maria Jose, additional, Luzardo Henriquez, Hugo Daniel, additional, Viguria Alegria, Maria De La Cruz, additional, Sanchez-Gonzalez, Blanca, additional, Roig, Monica, additional, Perez De Oteyza, Jaime, additional, Cabezudo, Elena, additional, Escoda, Lourdes, additional, de Oña, Raquel, additional, Queizan, Josë Antonio, additional, Infante, Maria Stefania, additional, Muntañola Prat, Ana, additional, and Lopez, Andres, additional

Published
2018
Full Text
View/download PDF

15. Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma.

Author

Oriol, Albert, Ibarra, Gladys, Abella, Eugènia, Motlló, Cristina, Cibeira, Maria-Teresa, Garcia, Antoni, Escoda, Lourdes, Granell, Miquel, Ben-Azaiz, Randa, Cervera, Marta, Cabezudo, Elena, Fernandez, Carlos, and Rosiñol, Laura

Subjects
QUALITY of life, OLDER patients, MULTIPLE myeloma, QUALITY of life measurement, TREATMENT duration, PLASMACYTOMA, MONOCLONAL gammopathies
Abstract

Multiple myeloma (MM) is a recurrent malignancy with a high impact on quality of life. Improved survival relies on the combination of drugs and extended duration of therapy, raising concerns on its toxicity burden in elderly patients. Health-related quality of life measurements attent to capture health aspects relevant to patients other than efficacy. This prospective study aimed to understand the relationship between MM-related symptomatology and other quality of life dimensions using the EORTC QLQ-MY20 questionnaire in individuals with relapsed or refractory MM. Irrespective of treatment modality, over 50% of patients who responded to treatment had significant omprovements of reported scores in all domains. Conversely, disease progression was associated with score deterioration not only in the MM-related symptoms domain but also in all other domains. HRQoL adds valuable information to the established efficacy endpoints but an adequate interpretation of HRQoL outcomes in randomized trials should require stratification according to response. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation

Author

Herrera, Sabina, primary, Pérez-López, Jordi, additional, Moltó-Abad, Marc, additional, Güerri-Fernández, Roberto, additional, Cabezudo, Elena, additional, Novelli, Silvana, additional, Esteve, Jordi, additional, Hernández, Albert, additional, Roig, Inmaculada, additional, Solanich, Xavier, additional, Prieto-Alhambra, Daniel, additional, Nogués, Xavier, additional, and Díez-Pérez, Adolfo, additional

Published
2017
Full Text
View/download PDF

17. Renal Response in Patients with Relapsed Refractory Multiple Myeloma: Interim Data of a Large, Observational, Prospective Study

Author

De La Rubia, Javier, primary, Salas, Queralt, additional, Morales, Enrique, additional, González, Esther, additional, Soledad Durán, Maria, additional, Escalante, Fernando, additional, Gironella, Mercedes, additional, González-López, Tomás José, additional, Duro, Rafael, additional, Pérez, Manuel, additional, Ribas, Paz, additional, Cabezudo, Elena, additional, Lluch, Rafael, additional, Español, Ignacio, additional, Cabañas, Valentin, additional, García-Muñoz, Ricardo, additional, Márquez, Jose Antonio, additional, Duran, Marta, additional, Soriano, Javier, additional, and García, Antoni, additional

Published
2016
Full Text
View/download PDF

18. Pomalidomide‐dexamethasone for treatment of soft‐tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.

Author

Jiménez‐Segura, Raquel, Granell, Miquel, Gironella, Mercè, Abella, Eugenia, García‐Guiñón, Antoni, Oriol, Albert, Cabezudo, Elena, Clapés, Victoria, Soler, Joan Alfons, Escoda, Lourdes, López-Pardo, Jordi, Fernández de Larrea, Carlos, Cibeira, Maria Teresa, Tovar, Natalia, Isola, Ignacio, Bladé, Joan, and Rosiñol, Laura

Subjects
MULTIPLE myeloma, THERAPEUTICS, PROGRESSION-free survival
Abstract

Objective: The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally and in patients treated with novel agents. Two types of plasmacytomas have being recognized: paraskeletal plasmacytomas (PPs) and extramedullary plasmacytomas (EMPs), being the incidence of EMPs lower but with worse prognosis. Our aim has been to analyze the efficacy of the pomalidomide‐dexamethasone combination in this patient profile. Method: In the present study, the efficacy of pomalidomide and dexamethasone in 21 patients from nine hospitals of Catalonia (Spain), with relapsed or refractory MM and Ps, was analyzed. For this purpose, we describe the evolution of paraprotein in serum and urine and the size of plasmacytomas during treatment with pomalidomide‐dexamethasone. Results: While 34% of the patients achieved a paraprotein response, only two patients with PPs (9%) responded (RC and PR). There were no responses among patients with EMPs. The median progression‐free survival from the start of treatment with pomalidomide/dexamethasone was only 1.7 months and the median overall survival of 4.5 months. Conclusion: In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft‐tissue plasmacytomas. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

19. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Author

Muñiz, Carmen, Martín-Martín, Lourdes, López, Antonio, Sánchez-González, Blanca, Salar, Antonio, Almeida, Julia, Sancho, Juan-Manuel, Ribera, José María, Heras, Cecilia, Peñalver, Francisco Javier, Gómez, Marta, González-Barca, Eva, Alonso, Natalia, Navarro, Belén, Olave, Teresa, Sala, Francisco, Conde, Eulogio, Márquez, José Antonio, Cabezudo, Elena, Cladera, Antonia, García-Malo, María, Caballero, María Dolores, and Orfao, Alberto

Published
2014
Full Text
View/download PDF

20. Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Author

Guerrero, Camila, Termini, Rosalinda, Garcés, Juan-José, Calasanz, Maria Jose, Ríos, Rafael, Cabezudo, Elena, Rosiñol, Laura, Joan, Bargay, Pérez-Montaña, Albert, Rocafiguera, Albert Oriol, Cabanas Perianes, Valentin, Najera, Maria-Josefa, Gonzalez Garcia, Esther, Ocio, Enrique M, Sureda Balari, Anna Maria, De Arriba, Felipe, Hernández Garcia, Miguel Teodoro, Garcia, Antonio, Martinez-Lopez, Joaquin, Blanchard, María-Jesús, Gonzalez Perez, Marta Sonia, Iglesias, Rebeca, Orfao, Alberto, Mateos, Maria Victoria, Lahuerta Palacios, Juan Jose, Bladé, Joan, San-Miguel, Jesus, Cedena, María T, Puig, Noemi, and Paiva, Bruno

Abstract

BACKGROUND

Published
2023
Full Text
View/download PDF

21. Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Author

Garcés, Juan-José, Termini, Rosalinda, Martín-Sánchez, Esperanza, Lasa, Marta, Perez, Jose J, Gutierrez, Norma C., Fernández, Manuela, Calasanz, Maria Jose, Rosiñol, Laura, Hernández Garcia, Miguel Teodoro, Oriol, Albert, Sureda Balari, Anna Maria, Perez Montaña, Albert, Ocio, Enrique M, Casanova Espinosa, Maria, Prosper, Felipe, Martinez-Lopez, Joaquin, Labrador, Jorge, Gonzalez Garcia, Esther, Ríos, Rafael, Escalante, Fernando, Bargay, Joan, Cabezudo, Elena, Cabañas, Valentín, Weinhold, Niels, Roccaro, Aldo, Avet-Loiseau, Herve, Orfao, Alberto, Blade Creixenti, Joan, Mateos, Maria Victoria, Lahuerta Palacios, Juan Jose, San-Miguel, Jesus, Cedena, María T, Puig, Noemi, and Paiva, Bruno

Abstract

Background:There is evidence suggesting that CTCs are responsible for the spreading of clonal plasma cells (PC) inside and outside the bone marrow (BM). However, some pts unexpectedly have no CTCs at diagnosis. Here, we hypothesize that the absence of CTC defines a specific MM subtype with unique biological and clinical features. To our knowledge, this has never been investigated.

Published
2023
Full Text
View/download PDF

22. Renal Response in Relapsed Refractory Multiple Myeloma Patients with Severe Renal Impairment at treatment Initiation: Intermediate Data of a Large, Observational, Prospective Study

Author

Garcia, Antoni, Salas, Queralt, Morales, Enrique, Esther, González, Duran, Maria Soledad, Escalante, Fernando, Gironella, Mercedes, Gonzalez, Tomás Jose, Duro, Rafael, Pérez, Manuel, Ribas, Paz, Cabezudo, Elena, Lluch, Rafael, Español, Ignacio, Cabañas, Valentin, Garcia, Ricardo Francisco, Márquez, Jose Antonio, Duran, Marta, Soriano, Javier, and de la Rubia, Javier

Published
2017
Full Text
View/download PDF

24. Renal Response in Patients (Pts) with Relapsed Refractory Multiple Myeloma (RRMM): Interim Data of a Large Observational, Prospective Study

Author

de la Rubia, Javier, primary, Morales, Enrique, additional, Escalante, Fernando, additional, Durán, Mª Soledad, additional, Perez Encinas, Manuel, additional, Gironella, Merche, additional, Gonzalez-Lopez, Tomas J, additional, Español, Ignacio, additional, Sarrà, Josep, additional, Cabezudo, Elena, additional, Gonzalez, Esther, additional, Calle, Carmen, additional, Martinez, Rafael, additional, Arnao, Mario, additional, González, Yolanda, additional, Márquez, José Antonio, additional, Cabañas, Valentin, additional, Blade, Joan, additional, Ruiz Boza, Antonio, additional, and Garcia, Antonio, additional

Published
2014
Full Text
View/download PDF

25. Linfocitosis B policlonal persistente: estudio de 35 casos

Author

Florensa, Lourdes, primary, Navarro, José Tomás, additional, Pérez Vila, María Encarnación, additional, Domingo, Alicia, additional, De la Banda, Esmeralda, additional, Rozman, Maria, additional, Camós, Mireia, additional, Millá, Fuensanta, additional, Perea, Granada, additional, Alonso, Esther, additional, Ayats, Ramon, additional, Aventín, Ana, additional, Cabezudo, Elena, additional, Espinet, Blanca, additional, Merino, Ana, additional, Romero, Pilar, additional, Sánchez, Carmen, additional, Tuset, Esperanza, additional, Solé, Francesc, additional, Feliu, Evarist, additional, Fernández, Cristalina, additional, Gallart, Miquel, additional, Vallespí, Teresa, additional, and Woessner, Soledad, additional

Published
2011
Full Text
View/download PDF

26. Postpartum ovarian vein thrombosis

Author

Ugarriza, Arancha, primary, Espax, Rosa, primary, Boixadera, Jordi, primary, Llorente, Andreu, primary, Escoda, Lourdes, primary, Cabezudo, Elena, primary, and Ortín, Xavier, additional

Published
2005
Full Text
View/download PDF

30. Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.

Author

Cejalvo MJ, Legarda M, Abella E, Cabezudo E, Encinas C, García-Feria A, Gironella M, Iñigo B, Martín J, Ribas P, Ruíz MÁ, González Y, Vicuña I, Ramírez Á, Fernández P, and de la Rubia J

Subjects
Aged, Disease-Free Survival, Female, Humans, Male, Middle Aged, Recurrence, Renal Dialysis, Retrospective Studies, Survival Rate, Antibodies, Monoclonal administration & dosage, Multiple Myeloma mortality, Multiple Myeloma therapy
Published
2020
Full Text
View/download PDF

31. [Persistent polyclonal B-cell lymphocytosis: study of 35 cases].

Author

Florensa L, Navarro JT, Pérez Vila ME, Domingo A, De la Banda E, Rozman M, Camós M, Millá F, Perea G, Alonso E, Ayats R, Aventín A, Cabezudo E, Espinet B, Merino A, Romero P, Sánchez C, Tuset E, Solé F, Feliu E, Fernández C, Gallart M, Vallespí T, and Woessner S

Subjects
Adult, B-Lymphocytes metabolism, Disease Progression, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Lymphocyte Activation, Lymphocytosis genetics, Lymphocytosis mortality, Male, Middle Aged, Retrospective Studies, Sex Distribution, Smoking, B-Lymphocytes pathology, Lymphocytosis immunology, Precancerous Conditions immunology
Abstract

Background and Objectives: Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare entity, presenting especially in adult smoker women. It is characterized by an increase of serum IgM, DR7-HLA haplotype, cytogenetic abnormalities and multiple IgH/BCL-2 rearrangements. To date, it has not been elucidated whether this is a benign or premalignant disorder. We analyzed the PPBL characteristics with especial attention to its evolution., Patients and Methods: Thirty-five PPBL patients from 5 hospitals in Catalonia were retrospectively analyzed. A simultaneous morphologic review of the blood smears was performed by members of the GCCH in a 16 multiple-observer optic microscope. Clinical and biological data were also analyzed., Results: PPBL presents in the majority of cases with persistent polyclonal B-cell lymphocytosis and affects primarily smoker women. The morphologic hallmark, in absence of viral infections, is the presence of activated lymphocytes with bilobulated and/or cleaved nuclei, and nuclear pockets in the ultrastructural study. Increased serum IgM, HLA-DR7 haplotype, chromosomal abnormalities such as i(3)(q10) and multiple IgH/BCL-2 rearrangements were detected. Thirty-four out of 35 patients are alive after a median follow up of 70.7 months. One patient died because of lung adenocarcinoma and another developed a follicular lymphoma without relation to PPBL., Conclusions: PPBL has an asymptomatic and stable evolution, although it frequently presents genetic abnormalities. It remains unknown whether it is a premalignant entity, similar to monoclonal gammopathies of unknown significance. Hence, accurate cytologic diagnosis and follow-up are essential., (Copyright © 2010 Elsevier España, S.L. All rights reserved.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results